HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

4th Edition of World Congress on Infectious Diseases

June 21-22, 2023 | Rome, Italy

June 21 -22, 2023 | Rome, Italy
Infection 2023

Kirga Kabo Abakar

Speaker at World Congress on Infectious Diseases 2023 - Kirga Kabo Abakar
Catholic University of Central Africa, Chad
Title : First detection of rifampin- and ofloxacin-resistant mycobacterium leprae in Chad (central africa)


Antimicrobial surveillance and identification of the genetic basis of antimicrobial resistance provides important information to optimize patient care. The present study was an analytical crosssectional study aimed at determining the prevalence of rifampicin and ofloxacin resistance genes among Mycobacterium leprae strains in three health districts in Chad. The determination of the folP1, rpoB and gyrA resistance genes was carried out by PCR-RLEP and confirmed by sequencing from 80 biopsy samples taken from patients with multibacillary leprosy, including 12 relapsed patients and 68 new cases. In the whole cohort, 1/80 (1.2%) showed resistance to rifampicin and 1/80 (1.2%) to ofloxacin. No mutations were detected for dapsone. The presence of M. leprae mutation associated with rifampicin resistance was observed in a relapsed patient and the mutation associated with ofloxacin resistance was observed in a patient with multibacillary leprosy who had not been sensitized by ofloxacin but should have used other quinolones. Both mutant strains revealed the emergence of secondary resistance. This study, the first to highlight the emergence of resistance to rifampicin and ofloxacin in Chad. It raises the need to implement a robust surveillance system to detect resistance of Mycobacterium leprae in Chad and even in Central Africa. Keywords: Mycobacterium leprae, resistance, Chad 3

Audience take away: 
We will present Chad in the health context of Sahelian developing countries and then explain the disease of leprosy, the drugs for the treatment . While highlighting the detection of the first resistances of rifampicin and ofloxacin: resistances of first line and second line treatment. These results would jeopardize the elimination of leprosy by 2030 set by the WHO.


Kirga Kabo Abakar studied at the Catholic University of Central Africa and obtained the Master's degree in Bacteriology and Virology in 2016. He is appointed as the Quality Assurance Manager at the CHU-the national reference in Ndjamena-Chad. I obtained my PhD in 2023 in the same university. After an internship of 6 months at CHU-Arnaud Devilleneuve France